• Home
  • Latest
  • Fortune 500
  • Finance
  • Tech
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia
Right Arrow Button IconLeft Arrow Button IconHome
Right Arrow Button IconPharmaceutical Industry

Pharmaceutical Industry

Page 90 of 100
MSMB Capital Management CIO Martin Shkreli
Health
This super-expensive drug is getting a $1 rival
By Benjamin SnyderOctober 23, 2015
J. Michael Pearson, chief executive officer, Valeant Pharmaceuticals International Inc., speaks during the Bloomberg Economic Series: Canada 2015 in Toronto, Ontario Thursday May 21/2015. (Photo by Kevin Van Paassen/Bloomberg)
Finance
Valeant short seller on pharmacy alliance: It’s the ‘turd in the punch bowl’
By Stephen GandelOctober 22, 2015
J. Michael Pearson, Chairman of the board and Chief Executive Officer of Valeant Pharmaceuticals International Inc., waits for the start of their annual general meeting in Laval, Quebec
Finance
Valeant’s accounting problems: It gets worse
By Stephen GandelOctober 22, 2015
Big pharma won’t stay silent in drug pricing debate for long
Health
Big pharma won’t stay silent in drug pricing debate for long
By Erika FryOctober 22, 2015
New Reasearch Shows That Aspirin May Cut Breast Cancer Risk
Health
The world’s biggest clinical trial is for one of the cheapest drugs
By Claire GrodenOctober 22, 2015
J. Michael Pearson, chief executive officer, Valeant Pharmaceuticals International Inc., speaks during the Bloomberg Economic Series: Canada 2015 in Toronto, Ontario Thursday May 21/2015. (Photo by Kevin Van Paassen/Bloomberg)
Finance
Forget the plunging stock price, here’s Valeant’s biggest problem
By Laura LorenzettiOctober 22, 2015
J. Michael Pearson, chief executive officer, Valeant Pharmaceuticals International Inc., speaks during the Bloomberg Economic Series: Canada 2015 in Toronto, Ontario Thursday May 21/2015. (Photo by Kevin Van Paassen/Bloomberg)
Health
Short-seller: Is Valeant the pharmaceutical Enron?
By Laura LorenzettiOctober 21, 2015
519891667
Health
Drug companies are paying huge sums to fast-track FDA approval
By Laura LorenzettiOctober 20, 2015
MSMB Capital Management CIO Martin Shkreli
Leadership
The face of high drug prices is trolling Bernie Sanders on Twitter
By Michal AddadyOctober 19, 2015
Marco Rubio
Leadership
Marco Rubio calls out high drug prices
By Ben GeierOctober 19, 2015
Parkinson’s patients show improvement after taking cancer drug
Health
Parkinson’s patients show improvement after taking cancer drug
By Claire ZillmanOctober 19, 2015
J. Michael Pearson, Chairman of the board and Chief Executive Officer of Valeant Pharmaceuticals International Inc., waits for the start of their annual general meeting in Laval, Quebec
Health
Valeant eases up on strategy to buy up ‘mispriced drugs’
By Laura LorenzettiOctober 19, 2015
J. Michael Pearson, Chairman of the board and Chief Executive Officer of Valeant Pharmaceuticals International Inc., waits for the start of their annual general meeting in Laval, Quebec
Health
Valeant beat expectations in 3Q thanks to U.S. skin business
By Reuters and Fortune EditorsOctober 19, 2015
Hillary Clinton in the first Democratic presidential debate in Las Vegas on Oct. 13
Commentary
Clinton’s big pharma takedown plan has some serious issues
By Chris Ford and Bethany CiancioloOctober 16, 2015
Democratic Candidates Attend New Hampshire Democratic Party Convention
Leadership
Bernie Sanders rejects drug price-raising CEO’s donation: ‘We don’t want his stinkin’ money’
By Michal AddadyOctober 16, 2015
1...
  • 88
  • 89
  • 90
  • 91
  • 92
...100
Most Popular
Success
Philanthropy leader at Warren Buffett and Bill Gates’ Giving Pledge says children of billionaires are pushing them to give their wealth away fasterplaceholder alt text
By Preston ForeSeptember 20, 2026
Success
Meet a 71-year-old who retired as a radiologist and professor, and now runs a banana-skewer business: ‘I never want to retire. Why would you do that?’placeholder alt text
By Preston ForeSeptember 20, 2026
Middle East
China suffers another setback in effort to de-dollarize global finance as anchor in the greenback's dominance quietly exits Beijing's payment schemeplaceholder alt text
By Jason MaSeptember 21, 2026
Fortune Secondary Logo
Rankings
  • 100 Best Companies
  • Fortune 500
  • Global 500
  • Fortune 500 Europe
  • Most Powerful Women
  • World's Most Admired Companies
  • See All Rankings
  • Lists Calendar
Sections
  • Finance
  • Fortune Crypto
  • Features
  • Leadership
  • Health
  • Commentary
  • Success
  • Retail
  • Mpw
  • Tech
  • Lifestyle
  • CEO Initiative
  • Asia
  • Politics
  • Conferences
  • Europe
  • Newsletters
  • Personal Finance
  • Environment
  • Magazine
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Fortune Brand Studio
  • Fortune Analytics
  • Fortune Conferences
  • Business Development
  • Group Subscriptions
About Us
  • About Us
  • Press Center
  • Work At Fortune
  • Terms And Conditions
  • Site Map
  • About Us
  • Press Center
  • Work At Fortune
  • Terms And Conditions
  • Site Map
  • Facebook icon
  • Twitter icon
  • LinkedIn icon
  • Instagram icon
  • TikTok icon
  • YouTube icon

    © 2026 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
    FORTUNE is a trademark of Fortune Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.